Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation - SPORTIF V


The goal of the randomized, double-blind SPORTIF V trial was to determine the safety and efficacy of a novel, oral direct thrombin inhibitor ximelagatran versus warfarin for prevention of stroke and systemic embolic events in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke.